Form 4: IGM Biosciences Director Julie Hambleton Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Director Julie Hambleton exercised stock options and sold shares of IGM Biosciences under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On July 25, 2024, Julie Hambleton, a director of IGM Biosciences, exercised stock options to acquire 15,132 shares of common stock at a price of $1.39 per share.
- Simultaneously, Hambleton sold 15,132 shares of common stock at $14 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on March 18, 2024.
- Following these transactions, Hambleton directly owns 2,000 shares of IGM Biosciences common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity under a pre-arranged plan.
Positives
- The use of a 10b5-1 trading plan suggests pre-planned and transparent trading activity.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the trading activities of company insiders, such as directors and officers.
Key Dates
| Date | Description |
|---|---|
| 03/18/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 07/25/2024 | Date of transaction: option exercise and share sale |
| 12/22/2028 | Expiration date of the stock options |
| 07/29/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.